- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.03. | Senti Biosciences, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 21.03. | Senti Biosciences GAAP EPS of -$0.42 | 2 | Seeking Alpha | ||
| 21.03. | Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights | 241 | GlobeNewswire (Europe) | - IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 - - Cash and anticipated receivables... ► Artikel lesen | |
| 21.03. | Senti Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | Senti Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 08.01. | Senti Bio cuts 37% of workforce to free funds for cell therapy cancer trials | 1 | Pharmaceutical Technology | ||
| 05.01. | Senti Biosciences to reduce workforce by 37% | 1 | Seeking Alpha | ||
| 05.01. | Senti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program | 258 | GlobeNewswire (Europe) | - Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024... ► Artikel lesen | |
| 05.01. | Senti Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.12.23 | Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate | 2 | Zacks | ||
| 22.12.23 | US STOCKS Cidara Therapeutics, Senti Bio, Lumentum Holdings | 10 | Reuters | ||
| 22.12.23 | Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today? | 2 | Benzinga.com | ||
| 22.12.23 | Senti Bio rises on FDA clearance to start trials on blood cancer therapy | 4 | Reuters | ||
| 22.12.23 | Senti Bio: FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic Malignancies | 3 | RTTNews | ||
| 22.12.23 | Senti Biosciences, Inc.: Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia | 233 | GlobeNewswire (Europe) | - First patient in Phase 1 clinical trial expected to be treated in Q2 2024 - - Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 - - SENTI-202 is a potential... ► Artikel lesen | |
| 22.12.23 | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.23 | Senti Biosciences GAAP EPS of -$0.77 misses by $0.33 | 2 | Seeking Alpha | ||
| 14.11.23 | Senti Biosciences GAAP EPS of -$0.83 misses by $0.39, revenue of $0.04M misses by $0.66M | 4 | Seeking Alpha | ||
| 13.11.23 | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,580 | -3,07 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,832 | -2,12 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,810 | -3,46 % | Collaboration advancing new sourdough strain: Ginkgo Bioworks working with Italian baking ingredients company | ||
| BEAM THERAPEUTICS | 21,500 | -5,45 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 0,985 | -0,51 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,530 | -5,16 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 25,900 | -4,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,840 | -2,96 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,520 | -1,62 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,720 | +0,07 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,750 | -3,61 % | How Vir found the one: CEO Marianne De Backer | ||
| VERVE THERAPEUTICS | 6,110 | -7,14 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 7,880 | -4,60 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,410 | -3,60 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,340 | -3,99 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen SENTI BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,21 % bei einem Aktienkurs von 0,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
